Newsletter Spring 2019 - note from the CEO Thomas Seoh (3)

Dear Friends of Kinexum, 


Welcome to the Spring 2019 edition of Kinexions, the Kinexum newsletter. 


Featured in this issue are two guest authors and two Kinexum authors: 


(1) Prasad Palthur, PhD, Co-founder and VP, Design and Development, of Innoneo Health System, on a comprehensive first installment of a series on artificial pancreas device systems, which I expect will prove to be a superb introduction and resource on this rapidly developing area of diabetes care; 

(2) John Kucharczyk, PhD, EVP at Healthgraph, and co-authors, on the use of blockchain in healthcare, including particularly clear explanations of terms and concepts; 

(3) Brian Oscherwitz, newly appointed Chief Operating Officer of Kinexum, on what he refers to as the Kinexum Advantage; and  

(4) Jennifer Zhao, Kinexum Associate, on her impressions of Kinexum, her first job after graduating from Dartmouth last year. 


As you may know, Kinexum is deeply involved in the Metabesity movement, a focus on chronic, non-communicable diseases of aging with at least some common metabolic roots (from diabetes and obesity to cardiovascular and neurodegenerative diseases to cancer and the aging process itself). Several weeks ago, Kinexum and international law firm Hogan Lovells presented a webcast on “Extending Human Lifespan – a Multi-Trillion Dollar Opportunity” – please click thislink for the YouTube video of the webcast. Additionally, Zan describes regulatory challenges that need to be overcome to target Metabesity in “Patients Experiment With Prescription Drugs to Fight Aging” – see the article by Kasier Health News here. 


We also have some fascinating webcasts coming up this spring, with star presenters such as: 

  • Ralph DeFronzo, MD, of University of Texas, San Antonio, author of over 750 publications, whose work has led to the approval of diabetes drugs such as metformin, dapagliflozin, empagliflozin, and canagliflozin, on the potential for prevention of type 2 diabetes, and 

  • Brian Leyland-Jones, MB, BS, PhD, of Avera Cancer Institute, previously affiliated with Stanford, Cornell, McGill, Emory, Memorial Sloan Kettering, and NCI, who has been involved in the development of about 70 anti-cancer compounds, including paclitaxel, on recent successes in treating cancer and preventing metastases through precision medicine. 


Happy reading! Please send me an email if you’d like to get together; I’ll be at Bio Europe Spring 2019 in Vienna at the end of March (where I will be on a panel on Metabesity), or ADA or BIO in early June!